Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
11.59
-0.13 (-1.07%)
Aug 14, 2025, 11:16 AM - Market open

Cartesian Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-36.26-77.42-219.7135.38-25.69
Depreciation & Amortization
2.521.150.841.291.25
Loss (Gain) From Sale of Assets
0.270.270.48-0.15-
Asset Writedown & Restructuring Costs
7.587.580.71--
Loss (Gain) From Sale of Investments
---0.08-0.380.06
Stock-Based Compensation
9.356.5822.5211.197.72
Other Operating Activities
-41.4643.96139.1-18.594.47
Change in Accounts Receivable
35.167.980.910.16-2.69
Change in Accounts Payable
-2.41-2.932.830.09-0.22
Change in Unearned Revenue
--5.855.26-64.71-45.5
Change in Income Taxes
----0.60.6
Change in Other Net Operating Assets
-8.69-4.99-4.034.68-0.39
Operating Cash Flow
-33.94-23.67-51.16-31.63-60.38
Capital Expenditures
-10.57-9.09-0.21-1.2-1.09
Sale of Property, Plant & Equipment
0.350.35---
Cash Acquisitions
--6.56--
Investment in Securities
--28.25-13.8-16.06
Investing Cash Flow
-10.22-8.7434.61-15-17.14
Long-Term Debt Repaid
---27.46--
Net Debt Issued (Repaid)
---27.46--
Issuance of Common Stock
125.61128.490.2339.3352.9
Other Financing Activities
-8.3-0.07-6.17-0.11-
Financing Cash Flow
117.31168.43-13.1539.2252.9
Foreign Exchange Rate Adjustments
0.01-0.02-0.050.02-0
Net Cash Flow
73.16135.99-29.75-7.4-24.63
Free Cash Flow
-44.51-32.77-51.37-32.83-61.47
Free Cash Flow Margin
-4338.60%-84.21%-197.53%-29.64%-72.25%
Free Cash Flow Per Share
-1.80-1.89-9.94-6.75-16.13
Cash Interest Paid
--1.852.252
Levered Free Cash Flow
-29.62-59.6728.9122.24-
Unlevered Free Cash Flow
-29.62-59.6730.6824.13-
Change in Working Capital
24.07-5.794.97-60.38-48.19
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q